WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named a Category Award Winner in the 2024 Clinical Trials Arena Excellence Awards, earning four awards across three categories: Innovation, Product Launches and Marketing.

马萨诸塞州沃尔瑟姆（商业新闻短讯）--人工智能驱动的分子和免疫分析解决方案的领先供应商BostonGene今天宣布，它已被提名为2024年临床试验领域卓越奖的类别奖得主，获得了三个类别的四个奖项：创新，产品发布和营销。

These awards underscore BostonGene’s continued commitment to revolutionizing cancer care and driving advancements in precision medicine..

这些奖项突显了BostonGene对彻底改变癌症护理和推动精准医学进步的持续承诺。。

Powered by GlobalData’s business intelligence, the Clinical Trials Arena Excellence Awards celebrate the most significant achievements and innovations in the industry, spotlighting companies and individuals who are driving meaningful change.

临床试验竞技场卓越奖由GlobalData的商业智能提供支持，旨在表彰业界最重要的成就和创新，突出推动有意义变革的公司和个人。

“We are proud to recognize BostonGene as a Category Award Winner in this year's Clinical Trials Arena Excellence Awards. Their innovative approach to precision medicine is setting a new standard in cancer care. BostonGene's commitment to advancing precision medicine and improving patient outcomes exemplifies the spirit of innovation that these awards celebrate,” said Tina Ross, Global Awards Manager at GlobalData..

GlobalData全球奖项经理蒂娜·罗斯（Tina Ross）表示：“我们很骄傲地承认，博斯通基因（BostonGene）是今年临床试验领域卓越奖（Clinical Trials Arena Excellence Awards）的类别奖项得主。他们对精准医学的创新方法正在癌症护理领域树立新标准。博斯通基因（BostonGene）致力于推进精准医学和改善患者预后，这体现了这些奖项所庆祝的创新精神。”。。

“We are honored to receive these prestigious awards. These awards reflect our commitment to transforming cancer care through innovation. We are dedicated to harnessing the power of AI to equip clinicians with the tools they need to deliver personalized, data-driven diagnostics to select treatments that improve patient outcomes.

“我们很荣幸获得这些久负盛名的奖项。这些奖项反映了我们通过创新改变癌症护理的承诺。我们致力于利用人工智能的力量，为临床医生提供所需的工具，以提供个性化的数据驱动诊断，以选择改善患者预后的治疗方法。

These recognitions reinforce our mission to lead the way in advancing precision oncology and we remain focused on pushing the boundaries of what’s possible in cancer treatment,” said Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene..

这些认识加强了我们领导推进精准肿瘤学的使命，我们仍然专注于推动癌症治疗可能的界限，”BostonGene首席科学官Joe Lennerz博士说。。

Innovation Award: Immune System Profiling Platform

创新奖：免疫系统分析平台

BostonGene earned the Innovation Award for its Immune System Profiling Platform and Clinical Pathway Navigator. The Immune System Profiling Platform provides a minimally invasive method to comprehensively analyze a patient’s immune system, offering vital insights for oncology treatments while reducing the need for repeated tissue biopsies..

BostonGene凭借其免疫系统分析平台和临床路径导航器获得了创新奖。免疫系统分析平台提供了一种微创方法来全面分析患者的免疫系统，为肿瘤治疗提供了重要的见解，同时减少了重复组织活检的需要。。

Innovation Award: Clinical Pathway Navigator

创新奖：临床路径导航

BostonGene earned the Innovation Award for the Clinical Pathway Navigator, which equips oncologists to make data-driven treatment decisions across more than 40 cancer types.

BostonGene获得了临床路径导航器创新奖，该奖项使肿瘤学家能够在40多种癌症类型中做出数据驱动的治疗决策。

Product Launches Award: AI-driven Pathology Platform

产品发布奖：人工智能驱动的病理学平台

BostonGene also won the Product Launches Award for its AI-based digital pathology platform and Unknown Primary test. The platform streamlines tissue analysis and minimizes human error, helping pathologists more accurately identify biomarkers and predict therapy responses. The Unknown Primary test plays a pivotal role in diagnosing metastatic cancers of unknown origin, empowering oncologists to make more informed treatment decisions..

BostonGene还凭借其基于AI的数字病理学平台和未知的初步测试获得了产品发布奖。。未知的主要测试在诊断未知来源的转移性癌症方面起着关键作用，使肿瘤学家能够做出更明智的治疗决策。。

Marketing Award: Digital Innovation

营销奖：数字创新

BostonGene’s new website, launched in summer 2023, earned the Marketing Award for its user-friendly design and wealth of resources tailored for patients, healthcare providers, and researchers. The website highlights BostonGene’s cutting-edge molecular profiling solutions, including Tumor Portrait™, Liquid Biopsy and Immunoprofiling.

BostonGene于2023年夏天推出的新网站因其用户友好的设计和为患者、医疗保健提供者和研究人员量身定制的丰富资源而获得了营销奖。该网站重点介绍了BostonGene的尖端分子分析解决方案，包括Tumor Portrait™、液体活检和免疫分析。

The site also features patient stories, financial assistance information and dynamic content to engage visitors and keep them informed on the latest developments in cancer care. The company’s digital strategy, including a substantial increase in LinkedIn followers and effective email marketing campaigns, has amplified BostonGene’s online presence and fostered stronger connections with its stakeholders..

该网站还提供患者故事、财务援助信息和动态内容，以吸引访问者，并让他们了解癌症护理的最新发展。该公司的数字战略，包括大幅增加LinkedIn粉丝和有效的电子邮件营销活动，扩大了BostonGene的在线影响力，并加强了与利益相关者的联系。。

About BostonGene Corporation

关于BostonGene Corporation

BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments.

BostonGene是一家专门从事先进计算生物学和精准医学的生物技术公司。BostonGene成立于2015年，一直在推动创新的界限，以改善患者护理并加速药物开发。我们的人工智能支持的多组学平台解码癌症患者的分子特征，包括他们的免疫系统和肿瘤微环境，以发现关键的疾病驱动因素，确定新的药物靶标并推荐最有效的治疗方法。

With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com..

凭借先进的生物分析技术、适应症特异性癌症文库和下一代CLIA认证、CAP认证的高复杂性实验室，我们提供了精确的、经过临床验证的见解，推动了精准医学和先进的肿瘤学研究。有关更多信息，请访问www.BostonGene.com。。